Year: 2025
Type: article
Abstract: Digital therapeutics (DTx) provide innovative treatment options. In this study, we identified and compared approved DTx in China, the US, Germany, and Belgium. In total, 507 DTx applications were identified (US, 192; China, 235; Germany, 55; Belgium, 25). China has approved the most, whereas the US initiated approval as early as 2017. In China, most DTx applications focus on disease treatment (88.09%), particularly for neurological (45.96%) and ophthalmic (21.28%) diseases. The US and Belgium emphasize disease management (US: 52.60%, Belgium: 72.00%), whereas Germany focuses on the treatment of mental and behavioral disorders (47.27%). Regarding therapeutic approaches, China's DTx predominantly utilizes computerized cognitive correction (26.38%), whereas the US and Belgium primarily rely on health status monitoring (US, 44.27%; Belgium, 80.00%). Germany's DTx primarily employs cognitive behavioral therapy (69.09%). An online database was established to ensure ease of access. Future studies should focus on generating further evidence to support the broader adoption of DTx.
Source: npj Digital Medicine
Institutions: Zhejiang Chinese Medical University, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Hangzhou Medical College, Southwest Medical University, NetEase (China), Fudan University, Guiyang Medical University, Affiliated Hospital of Guizhou Medical University, Peking University, Affiliated Hospital of Southwest Medical University
Language: English
Subfield: Applied Psychology
Field: Psychology
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $4,090
Awards: 易用性激励HIT 质量和效果的作用和机制研究, G8428368502
OpenAlex ID: W4410724314